No Benefit of Bimagrumab in Sporadic Inclusion Body Myositis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT
Neurology 2021 Mar 23;96(12)e1595-e1607, AA Amato, MG Hanna, PM Machado, UA Badrising, H Chinoy, O Benveniste, AK Karanam, M Wu, LB Tankó, AA Schubert-Tennigkeit, DA Papanicolaou, TE Lloyd, M Needham, C Liang, KA Reardon, M de Visser, DP Ascherman, RJ Barohn, MM Dimachkie, JAL Miller, JT Kissel, B Oskarsson, NC Joyce, P Van den Bergh, J Baets, JL De Bleecker, C Karam, WS David, M Mirabella, SP Nations, HH Jung, E Pegoraro, L Maggi, C Rodolico, M Filosto, AI Shaibani, K Sivakumar, NA Goyal, M Mori-Yoshimura, S Yamashita, N Suzuki, M Aoki, M Katsuno, H Morihata, K Murata, H Nodera, I Nishino, CD Romano, VSL Williams, J Vissing, L Zhang AubersonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.